New Clinical Data Show Patients Receiving Cialis - tadalafil - Improved Intercourse Success at 24 and 36 Hours After Dosing
Sunday, July 27th, 2008According to newly released clinical data on Cialis(TM), an investigational PDE5 inhibitor being developed by Lilly ICOS LLC for the treatment of erectile dysfunction (ED), men with ED reported a statistically significant improvement in successful intercourse attempts at 24 and 36 hours after taking the drug, compared to placebo.
These and other new findings - including a summary of cardiovascular safety data that showed no increased incidence of cardiovascular events during clinical studies - are being presented at the 97th Annual Meeting of the American Urological Association.
Cialis Period of Effectiveness - Key Study Findings:
In a Phase III clinical study designed to evaluate the efficacy of Cialis at specific time points after dosing, 1348 men with mild-to-severe ED were randomly assigned to receive Cialis 20 mg (n=175) or placebo (n=173) over approximately an eight-week period. Patients were instructed to attempt intercourse with their partners on four specific occasions: on two occasions at 24 hours after dosing and on two occasions at 36 hours after dosing. The primary endpoint was the percentage of successful sexual intercourse attempts.